---
title: "This Cancer Treatment Stock Nears A Buy Point As Quarterly Results Loom"
description: "Zai Lab stock is in a cup-with-handle base before Q2 results due Thursday."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251881360.md"
published_at: "2025-08-06T17:25:00.000Z"
---

# This Cancer Treatment Stock Nears A Buy Point As Quarterly Results Loom

> Zai Lab stock is in a cup-with-handle base before Q2 results due Thursday.

Zai Lab stock is in a cup-with-handle base before Q2 results due Thursday.

### Related Stocks

- [ZLAB.US - Zai Lab](https://longbridge.com/en/quote/ZLAB.US.md)
- [09688.HK - ZAI LAB](https://longbridge.com/en/quote/09688.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Zai Lab Sets February 26 Board Meeting to Approve and Release 2025 Annual Results | Zai Lab Ltd has scheduled a board meeting for February 26, 2026, to approve its audited financial results for the year e | [Link](https://longbridge.com/en/news/275665019.md) |
| Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Update | Lonza Group Ag (OTCMKTS:LZAGY) experienced a significant decline in short interest, dropping 20.9% to 21,908 shares as o | [Link](https://longbridge.com/en/news/276006871.md) |
| Qatar General Insurance & Reinsurance FY Profit Rises | QATAR GENERAL INSURANCE & REINSURANCE COMPANY :FY NET PROFIT 124.4 MILLION RIYALS VERSUS 29 MILLION RIYALS YEAR AGOH2 CA | [Link](https://longbridge.com/en/news/276064351.md) |
| MBV International Says Unit To Sell 20,000 Ordinary Shares In Lordan Group At HK$31.4 Mln | MBV International Ltd :UNIT TO SELL 20,000 ORDINARY SHARES IN LORDAN GROUP AT HK$31.4 MILLION | [Link](https://longbridge.com/en/news/276043299.md) |
| Benjamin Palleiko Sells 3,354 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock | KalVista Pharmaceuticals CEO Benjamin Palleiko sold 3,354 shares at $15.70 each, totaling $52,657.80, reducing his owner | [Link](https://longbridge.com/en/news/275978075.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.